drugset
Drugs / EO4010
last change May 2025 re-read 3 minutes ago

EO4010

Vaccine

Developed for
colorectal cancer
Investigated by
Enterome

Trials 1

today NCT05589597 · Ph 1/2
202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/2 NCT05589597 Jun 2023 → May 2025 colorectal cancer Enterome Terminated No outcome recorded Stop: Enrollment

Press releases naming this drug 3 releases

DateIssuerRelease
2025-05-30 Enterome Enterome presents positive Phase 1/2 MSS/pMMR metastatic colorectal cancer data in patients treated with EO4010 OncoMimics™ immunotherapy plus nivolumab at ASCO 2025 enterome.com ↗
2024-12-11 Enterome Enterome Presents Encouraging Initial Clinical Data on EO4010 in Colorectal Cancer at ESMO IO 2024 enterome.com ↗
2023-06-30 Enterome Enterome announces first patient dosed in a Phase 1/2 trial with third OncoMimics™ immunotherapy, EO4010, in Metastatic Colorectal Cancer enterome.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as EO4010 ClinicalTrials.gov intervention name — accepted as the source's own label NCT05589597 ↗
Modality Vaccine “microbial-derived therapeutic vaccine EO4010” NCT05589597 ↗